Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/10891
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | ASSAM NKOUIBERT, Pryseley | - |
dc.contributor.author | TILAHUN ESHETE, Abel | - |
dc.contributor.author | ALONSO ABAD, Ariel | - |
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.date.accessioned | 2010-04-21T10:44:27Z | - |
dc.date.available | NO_RESTRICTION | - |
dc.date.available | 2010-04-21T10:44:27Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | COMPUTATIONAL STATISTICS & DATA ANALYSIS, 54(5). p. 1342-1354 | - |
dc.identifier.issn | 0167-9473 | - |
dc.identifier.uri | http://hdl.handle.net/1942/10891 | - |
dc.description.abstract | The number of potential surrogate markers for clinical-trial endpoints is increasing rapidly, not in the least owing to the availability of biomarkers. At the same time, considerable development has taken place regarding statistical evaluation paradigms for such markers. As a consequence, such endpoints are given more extensive consideration for practice than previously had been the case. A particular but important instance is where the true endpoint is the ultimate assessment in a sequence of repeated measures. It is then appealing to consider earlier measures, either in isolation or several combined, as a potential surrogate endpoint. The length and cost reducing potential has to be weighed carefully against loss in precision and the risks of an inappropriate decision regarding a new compound's fate. Quantitative criteria to do so are developed, embedded in a meta-analytic framework. The methodology's behavior is assessed through simulations and applied to data from a pair of clinical trials, one in ophthalmology and one in schizophrenia. (C) 2009 Elsevier B.V. All rights reserved. | - |
dc.description.sponsorship | Financial support from the IAP research network #P6/03 of the Belgian Government (Belgian Science Policy) is gratefully acknowledged. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.rights | © 2009 Elsevier B.V. All rights reserved. | - |
dc.subject.other | biomarker; cost function; opthalmology; schizophrenia | - |
dc.title | Using earlier measures in a longitudinal sequence as a potential surrogate for a later one | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1354 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 1342 | - |
dc.identifier.volume | 54 | - |
local.format.pages | 13 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Molenberghs, Geert] Univ Hasselt, Ctr Stat, Interuniv Inst Biostat & Stat Bioinformat, B-3590 Diepenbeek, Belgium. [Molenberghs, Geert] Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, Louvain, Belgium. geert.molenberghs@uhasselt.be | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1016/j.csda.2009.11.024 | - |
dc.identifier.isi | 000276085800012 | - |
item.validation | ecoom 2011 | - |
item.contributor | ASSAM NKOUIBERT, Pryseley | - |
item.contributor | TILAHUN ESHETE, Abel | - |
item.contributor | ALONSO ABAD, Ariel | - |
item.contributor | MOLENBERGHS, Geert | - |
item.accessRights | Open Access | - |
item.fullcitation | ASSAM NKOUIBERT, Pryseley; TILAHUN ESHETE, Abel; ALONSO ABAD, Ariel & MOLENBERGHS, Geert (2010) Using earlier measures in a longitudinal sequence as a potential surrogate for a later one. In: COMPUTATIONAL STATISTICS & DATA ANALYSIS, 54(5). p. 1342-1354. | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 0167-9473 | - |
crisitem.journal.eissn | 1872-7352 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
optend10[1].pdf | Peer-reviewed author version | 190.07 kB | Adobe PDF | View/Open |
Pryseley.pdf Restricted Access | Published version | 595.28 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.